Apolipoprotein mimetic peptides dramatically reduce atherosclerosis in animal models, and may be an excellent mode of therapy to treat a variety of vascular inflammatory conditions, including atherosclerosis. Studies of apolipoprotein mimetic peptides in models of inflammatory disorders other than atherosclerosis, including viral influenza, asthma, chronic rejection after heart transplantation, sickle cell disease, scleroderma, diabetes, cognitive dysfunction and renal inflammation, suggest that apolipoprotein mimetic peptides may have efficacy in a wide range of inflammatory conditions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856620 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Membrane scaffold proteins-based nanodiscs (NDs) have facilitated unprecedented structural and biophysical analysis of membrane proteins in a near-native lipid environment. However, successful reconstitution of membrane proteins in NDs requires prior solubilization and purification in detergents, which may impact their physiological structure and function. Furthermore, the detergent-mediated reconstitution of NDs is unlikely to recapitulate the precise composition or asymmetry of native membranes.
View Article and Find Full Text PDFLipoxin A improves cardiac remodeling and function in diabetes-associated cardiac dysfunction.
Cardiovasc Diabetol
November 2024
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Background: Diabetic heart disease may eventually lead to heart failure, a leading cause of mortality in diabetic individuals. The lack of effective treatments for diabetes-induced heart failure may result from a failure to address the underlying pathological processes, including chronic, low-grade inflammation. Previous studies have reported that lipoxin A (LXA), known to promote resolution of inflammation, attenuates diabetes-induced atherosclerosis, but its impact on diabetic hearts has not been sought.
View Article and Find Full Text PDFAn apolipoprotein E receptor mimetic peptide decreases blood-brain barrier permeability following intracerebral hemorrhage by inhibiting the CypA/MMP-9 signaling pathway via LRP1 activation.
Int Immunopharmacol
December 2024
The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, Guizhou Province, PR China. Electronic address:
Apolipoprotein (Apo) E mimetic peptides down-regulate the inflammatory response and alleviate damage to secondary neurons after intracerebral hemorrhage (ICH). We designed a novel apoE receptor mimetic composed of the low-density lipoprotein receptor-associated protein-1 (LRP1) receptor-binding domain of apoE with 6 lysines (6KApoEp). The 6KApoEp peptide is small enough to penetrate the blood-brain barrier (BBB) and modulate the inflammatory response during damage to the central nervous system.
View Article and Find Full Text PDFApolipoprotein A-I Mimetic Peptide Restores VEGF-induced Angiogenesis in Hypercholesterolemic Ischemic Heart by Reducing HDL Proinflammatory Properties.
J Cardiovasc Transl Res
October 2024
Division of Cardiac Surgery, Cardiovascular Diseases Institute, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhong Shan Er Road, Guangzhou, 510080, China.
Article Synopsis
- VEGF-induced angiogenesis is hindered in hypercholesterolemia, but a peptide called D-4F may help improve this condition by reducing HDL's pro-inflammatory effects.
- In a study, different mouse models were used to assess the impact of D-4F and VEGFA on heart function and angiogenesis after inducing a heart attack.
- The results indicated that D-4F, when combined with VEGFA, enhanced angiogenesis and improved heart function in hypercholesterolemic mice by activating specific signaling pathways, although it did not have the same effect in another set of genetically modified mice.
High-Density Lipoprotein Mimetic Peptide 4F Reduces Toxic Amyloid-Beta Exposure to the Blood-Brain Barrier Endothelium in Alzheimer's Disease Transgenic Mice.
Mol Pharm
November 2024
Department of Pharmaceutics and Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Article Synopsis
- * The HDL mimetic peptide 4F shows promise as a treatment, as it significantly reduces the blood-to-brain influx of Aβ in both wild-type and APP/PS1 transgenic mice.
- * 4F lowers Aβ-induced activation of the p38 pathway in endothelial cells, suggesting it may help protect the BBB and reduce Aβ accumulation, offering potential therapeutic avenues for AD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!